Aclaris Therapeutics (ACRS) AI Stock Analysis

• Market Cap: $255.66M
• Dividend Yield: N/A
• Average Volume (3M): 1.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: -41.87%
• EPS Growth: -165.76%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.12
• Shares Outstanding: 108,332,214
• 10 Day Avg. Volume: 1,094,755
• 30 Day Avg. Volume: 1,106,653
• PEG Ratio: -0.04
• Price to Book (P/B): 1.23
• Price to Sales (P/S): 10.24
• P/FCF Ratio: -9.49
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: 4.87
• Enterprise Value/Gross Profit: 21.60
• Enterprise Value/Ebitda: -1.22
• 1Y Price Target: $9.25
• Price Target Upside: 283.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $2.00 ▼(-17.01% Downside)

The overall stock score is primarily impacted by the company's financial challenges, including declining revenues and negative profitability. Technical analysis provides some positive momentum, but valuation concerns due to negative earnings and lack of dividends weigh heavily on the score. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Low Leverage

A low debt-to-equity ratio indicates financial prudence, providing flexibility to invest in growth opportunities without heavy debt burdens.

Strong Equity Base

A strong equity base enhances financial stability, allowing the company to withstand economic fluctuations and invest in long-term projects.

Cash Conversion Efficiency

Efficient conversion of net income to free cash flow supports operational sustainability, enabling reinvestment into R&D and strategic initiatives.

Negative Factors

Declining Revenue

Declining revenues suggest challenges in market demand or competitive positioning, potentially impacting long-term growth and profitability.

Negative Profitability

Negative profitability indicates operational inefficiencies and challenges in cost management, which could hinder future investment and growth potential.

Operational Challenges

Negative EBIT and EBITDA margins reflect ongoing operational difficulties, suggesting the need for strategic adjustments to improve efficiency and profitability.

Aclaris Therapeutics Business Overview & Revenue Model

Company Description

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

How the Company Makes Money

Aclaris Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may receive funding through various streams, including upfront payments and milestone payments from partnerships with larger pharmaceutical companies, as well as royalties on product sales. Additionally, Aclaris may also generate revenue from licensing agreements that allow other companies to develop or market its drug candidates. The company actively seeks collaborations to enhance its research capabilities and expand its market reach, which contributes to its overall earnings.

Aclaris Therapeutics Financial Statement Overview

Summary

Aclaris Therapeutics faces significant financial challenges, with declining revenues and negative profitability metrics. The balance sheet shows low leverage, but the company struggles with negative returns on equity. Cash flow metrics indicate operational inefficiencies, although there is some ability to convert income to cash flow. Overall, the company needs to address its profitability and cash flow issues to improve its financial health.

Income Statement

Aclaris Therapeutics has experienced declining revenue with a negative growth rate of -5.56% in the TTM. The company shows weak profitability with a negative net profit margin of -8.02% and a gross profit margin of 24.18%. The EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.018, suggesting limited leverage. However, the return on equity is significantly negative at -95.92%, reflecting poor profitability. The equity ratio stands at 69.65%, indicating a strong equity base relative to total assets.

Cash Flow

Aclaris Therapeutics has a negative free cash flow growth rate of -4.76% in the TTM, and the operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is positive at 4.59, suggesting some efficiency in converting net income to free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.74M	18.72M	31.25M	29.75M	6.76M	6.48M
Gross Profit	3.55M	15.93M	13.17M	17.79M	2.05M	1.35M
EBITDA	-62.78M	-51.72M	-115.45M	-84.36M	-64.46M	-47.20M
Net Income	-141.68M	-132.06M	-88.48M	-86.91M	-90.86M	-51.02M
Balance Sheet
Total Assets	175.53M	220.33M	197.41M	254.60M	251.21M	70.78M
Cash, Cash Equivalents and Short-Term Investments	95.91M	113.59M	119.11M	217.57M	191.41M	54.13M
Total Debt	2.24M	0.00	426.00K	684.00K	693.00K	11.26M
Total Liabilities	55.43M	64.77M	40.23M	56.98M	53.87M	33.13M
Stockholders Equity	120.10M	155.55M	157.18M	197.62M	197.34M	37.65M
Cash Flow
Free Cash Flow	-78.82M	-20.20M	-79.63M	-68.17M	-52.44M	-39.09M
Operating Cash Flow	-42.92M	-20.07M	-78.33M	-67.57M	-52.13M	-38.63M
Investing Cash Flow	-50.73M	-69.77M	46.22M	12.63M	-167.63M	6.39M
Financing Cash Flow	71.25M	74.54M	26.71M	72.87M	225.05M	18.37M

Aclaris Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.41
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRS, the sentiment is Positive. The current price of 2.41 is above the 20-day moving average (MA) of 2.29, above the 50-day MA of 2.07, and above the 200-day MA of 1.74, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 57.59 is Neutral, neither overbought nor oversold. The STOCH value of 28.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACRS.

Aclaris Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MDXH	50 Neutral	$235.61M	-5.44	―	―	22.56%	41.62%
SERA	49 Neutral	$97.06M	―	-44.24%	―	0.93%	13.99%
ACRS	48 Neutral	$255.66M	-1.72	-113.23%	―	-41.87%	-165.76%
STIM	43 Neutral	$147.93M	―	-239.53%	―	78.62%	32.39%
NOTV	41 Neutral	$39.16M	-0.42	-48.46%	―	0.85%	29.83%
XGN	41 Neutral	$217.34M	―	-122.81%	―	14.08%	1.34%

Aclaris Therapeutics Corporate Events

Aclaris Therapeutics’ ATI-045 Study: A Potential Game-Changer for Atopic Dermatitis

Study Overview: Aclaris Therapeutics Inc. is conducting a study titled A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients With Moderate-to-Severe Atopic Dermatitis. The study aims to assess the effectiveness and safety of ATI-045, a potential treatment for atopic dermatitis, a condition affecting millions worldwide.

Aclaris Therapeutics Hosts R&D Day for Innovations

On October 14, 2025, Aclaris Therapeutics will hold an R&D Day to showcase their innovative therapeutic developments. The company is advancing several promising product candidates, including bosakitug, ATI-052, and ATI-2138, which have the potential to be best-in-class treatments for various immune-mediated diseases. Aclaris is well-financed with a cash runway extending into 2028, and they are poised for significant growth with multiple clinical programs and strategic partnerships on the horizon.

The most recent analyst rating on (ACRS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.

Aclaris Therapeutics Reports Q2 2025 Results and Updates

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for immuno-inflammatory diseases, leveraging a robust research and development engine to address unmet patient needs.